Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
Radiother Oncol. 2018 Mar;126(3):424-430. doi: 10.1016/j.radonc.2017.12.008. Epub 2018 Jan 3.
A population-based cohort and four randomized trials enriched with long-term register data were used to clarify if radiotherapy in combination with rectal cancer surgery is associated with increased risks of cardiovascular disease (CVD).
We identified 14,901 rectal cancer patients diagnosed 1995-2009 in Swedish nationwide registers, of whom 9227 were treated with preoperative radiotherapy. Also, we investigated 2675 patients with rectal cancer previously randomized to preoperative radiotherapy or not followed by surgery in trials conducted 1980-1999. Risks of CVD overall and subtypes were estimated based on prospectively recorded hospital visits during relapse-free follow-up using multivariable Cox regression. Maximum follow-up was 18 and 33 years in the register and trials, respectively.
We found no association between preoperative radiotherapy and overall CVD risk in the register (Incidence Rate Ratio, IRR = 0.99, 95% confidence interval (CI) 0.92-1.06) or in the pooled trials (IRR = 1.07, 95% CI 0.93-1.24). We noted an increased risk of venous thromboembolism among irradiated patients in both cohorts (IRR = 1.41, 95% CI 1.15-2.72; IRR = 1.41, 95% CI 0.97-2.04), that remained during the first 6 months following surgery among patients treated 2006-2009, after the introduction of antithrombotic treatment (IRR = 2.30, 95% CI 1.01-5.21). However, the absolute rate difference of venous thromboembolism attributed to RT was low (10 cases per 1000 patients and year).
Preoperative radiotherapy did not affect rectal cancer patients' risk of CVD overall. Although an excess risk of short-term venous thromboembolism was noted, the small increase in absolute numbers does not call for general changes in routine prophylactic treatment, but might do so for patients already at high risk of venous thromboembolism.
本研究通过基于人群的队列研究和四项纳入长期登记数据的随机试验,旨在明确直肠癌手术联合放疗是否会增加心血管疾病(CVD)风险。
我们在瑞典全国登记处中确定了 1995-2009 年间诊断为直肠癌的 14901 例患者,其中 9227 例接受了术前放疗。此外,我们还研究了 1980-1999 年进行的随机试验中 2675 例接受或未接受术前放疗的直肠癌患者。在无复发生存随访期间,通过前瞻性记录的住院就诊情况,利用多变量 Cox 回归估计 CVD 总体和亚型的风险。在登记处和试验中,最长随访时间分别为 18 年和 33 年。
我们在登记处(发生率比[IRR],0.99;95%置信区间[CI],0.92-1.06)或汇总试验(IRR,1.07;95%CI,0.93-1.24)中均未发现术前放疗与总体 CVD 风险之间存在关联。我们在两个队列中均发现接受放疗的患者静脉血栓栓塞风险增加(IRR,1.41;95%CI,1.15-2.72;IRR,1.41;95%CI,0.97-2.04),在 2006-2009 年接受治疗的患者中,在手术后的前 6 个月内,在抗血栓治疗引入后,该风险仍然存在(IRR,2.30;95%CI,1.01-5.21)。然而,归因于 RT 的静脉血栓栓塞的绝对风险差异较小(每 1000 例患者和年 10 例)。
术前放疗并未影响直肠癌患者总体 CVD 风险。尽管注意到短期静脉血栓栓塞风险增加,但绝对数量的微小增加并不需要常规预防性治疗的普遍改变,但对于已经处于高静脉血栓栓塞风险的患者可能需要改变。